ADAP News and Press, Adaptimmune Therapeutics plc From 11/08/22

New responses in ovarian and urothelial cancers increase ORR to 52% from 44% in heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers after single dose of ADP-A2M4CD8  Across the entire ongoing Phase 1 SURPASS trial, the ORR has increased to 37%...

Adaptimmune ( NASDAQ: ADAP ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open. The consensus EPS Estimate is -$0.28 (-460.0% Y/Y) and the consensus Revenue Estimate is $4.97M (+314.2% Y/Y). Over the last 3 months, EPS estimates ...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 27, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2022, be...

Summary The second patient death prompted Alpine to terminate any future development of davoceticept. It's prudent that Alpine stopped unfruitful developments early on to focus on lower-hanging fruits. Next year, Alpine is poised to run basket studies on ALPN303 which can move...

Adaptimmune Therapeutics ( NASDAQ: ADAP ) on Tuesday said that GSK ( NYSE: GSK ) was transferring back cancer therapy programs NY-ESO and PRAME. In 2014 the two companies signed a collaboration and license agreement, for up to five programs. In 2017, ...

Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 – GSK to deliver data from the ongoing Phase 2 / potential registrational trial with lete-cel in sarcoma with final readouts expected in late 2023 – Adaptimmune will continue t...

Summary Adaptimmune Therapeutics plans to file a BLA this year. Despite that, the stock remains depressed. Their cash position is difficult as well. For further details see: Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this event. For further details see: Adaptimmune Therapeutics (ADAP) Presents At ESMO Congress 2022 - Slideshow

U.K.-based biotech Adaptimmune Therapeutics plc ( NASDAQ: ADAP ) announced new data Friday from its Phase 1 SURPASS trial for anti-cancer agent ADP-A2M4CD8 in patients with solid tumors. The data will be part of a presentation at the European Society for Medical Oncology (ES...